Share on StockTwits

Shares of Amedisys (NASDAQ:AMED) have been given a consensus rating of “Hold” by the ten analysts that are currently covering the company, reports. Four investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $11.14.

AMED has been the subject of a number of recent research reports. Analysts at Avondale Partners downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, June 2nd. Separately, analysts at Piper Jaffray cut their price target on shares of Amedisys from $13.00 to $12.00 in a research note on Monday, May 12th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Amedisys in a research note on Thursday, March 27th. They now have a $15.00 price target on the stock.

Amedisys (NASDAQ:AMED) opened at 13.525 on Wednesday. Amedisys has a 1-year low of $9.51 and a 1-year high of $18.70. The stock’s 50-day moving average is $14.09 and its 200-day moving average is $14.8. The company’s market cap is $443.8 million.

Amedisys (NASDAQ:AMED) last announced its earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by $0.63. The company had revenue of $298.74 million for the quarter, compared to the consensus estimate of $301.89 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s revenue for the quarter was down 9.1% on a year-over-year basis. On average, analysts predict that Amedisys will post $0.03 earnings per share for the current fiscal year.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.